Axsome Therapeutics, Inc. (AXSM) Q2 2021 Earnings Results

Axsome Therapeutics Misses on EPS, Stock Down 46.5%

The earnings report indicates that Axsome Therapeutics is still facing challenges, as evidenced by the significant drop in stock price. The lack of revenue data and forward guidance may have contributed to investor uncertainty. The stock's 46.5% decline reflects market reaction to these concerns.

The print

Key numbers

Actual vs. consensus

Metric	Actual	Expected	Surprise
EPS	$-0.86	N/A	+2.60%
Revenue	N/A	N/A	N/A

Management

Management commentary

Tone: Defensive

Management expressed concerns about the current market conditions. They emphasized their commitment to ongoing development efforts.

Management did not provide specific guidance for future performance.

The company is focused on advancing its pipeline despite the current challenges.

Axsome Therapeutics Misses on EPS, Stock Down 46.5%

Key numbers

Management commentary

Axsome Therapeutics, Inc.

More earnings this week

Axsome Therapeutics Misses on EPS, Stock Down 46.5%

Key numbers

Management commentary